TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Journal:

Nature Medicine

Published:

2025-06-11

DOI:

10.1038/s41591-025-03722-7

Affiliations:

7

Authors:

13

Go to article

Institutions	Authors	Share
Terns Pharmaceuticals, Inc., United States of America (USA)	7.000000	0.54
Houston Methodist Hospital, United States of America (USA)	1.000000	0.08
Arizona Liver Health, United States of America (USA)	1.000000	0.08
The University of Texas at San Antonio (UT San Antonio), United States of America (USA)	1.000000	0.08
Washington State University (WSU), United States of America (USA)	1.000000	0.08
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.08
Pinnacle Clinical Research, United States of America (USA)	1.000000	0.08

Interested in Clinical Sciences?